{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:16:45Z","timestamp":1791235005942,"version":"4.1.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Fosfomycin has shown promising\n            <jats:italic>in vitro<\/jats:italic>\n            activity against multidrug-resistant (MDR) urinary pathogens; however, clinical data are lacking. We conducted a retrospective chart review to describe the microbiological and clinical outcomes of urinary tract infections (UTIs) with MDR pathogens treated with fosfomycin tromethamine. Charts for 41 hospitalized patients with a urine culture for an MDR pathogen who received fosfomycin tromethamine from 2006 to 2010 were reviewed. Forty-one patients had 44 urinary pathogens, including 13 carbapenem-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            (CR-Kp), 8\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            , and 7 vancomycin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterococcus faecium<\/jats:named-content>\n            (VRE) isolates, 7 extended-spectrum beta-lactamase (ESBL) producers, and 9 others.\n            <jats:italic>In vitro<\/jats:italic>\n            fosfomycin susceptibility was 86% (median MIC, 16 \u03bcg\/ml; range, 0.25 to 1,024 \u03bcg\/ml). Patients received an average of 2.9 fosfomycin doses per treatment course. The overall microbiological cure was 59%; failure was due to either relapse (24%) or reinfection UTI (17%). Microbiological cure rates by pathogen were 46% for CR-Kp, 38% for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n            , 71% for VRE, 57% for ESBL producers, and 100% for others. Microbiological cure (\n            <jats:italic>n<\/jats:italic>\n            = 24) was compared to microbiological failure (\n            <jats:italic>n<\/jats:italic>\n            = 17). There were significantly more solid organ transplant recipients in the microbiological failure group (59% versus 21%;\n            <jats:italic>P<\/jats:italic>\n            = 0.02). None of the patients in the microbiological cure group had a ureteral stent, compared to 24% of patients within the microbiological failure group (\n            <jats:italic>P<\/jats:italic>\n            = 0.02). Fosfomycin demonstrated\n            <jats:italic>in vitro<\/jats:italic>\n            activity against UTIs due to MDR pathogens. For CR-KP, there was a divergence between\n            <jats:italic>in vitro<\/jats:italic>\n            susceptibility (92%) and microbiological cure (46%). Multiple confounding factors may have contributed to microbiological failures, and further data regarding the use of fosfomycin for UTIs due to MDR pathogens are needed.\n          <\/jats:p>","DOI":"10.1128\/aac.00402-12","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T02:58:44Z","timestamp":1346122724000},"page":"5744-5748","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":152,"title":["Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant Organisms"],"prefix":"10.1128","volume":"56","author":[{"given":"Elizabeth A.","family":"Neuner","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sekeres","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerri S.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_1_3_2","volume-title":"CLSI document M100-S21.","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02494-07"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkl315","article-title":"Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance","volume":"58","author":"Ellington MJ","year":"2006","unstructured":"EllingtonMJ LivermoreDM PittTL HallLM WoodfordN. 2006. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J. Antimicrob. Chemother. 58:848\u2013852.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01235-09"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0456-4"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70325-1"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.03.021"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. 2009. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transpl. 9(Suppl 3):S1\u2013S155.","journal-title":"Am. J. Transpl."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2001.00204.x"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00349-11"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_1_14_2","unstructured":"MandellGL\nBennettJE\nDolinR. 2010. Mandell Douglas and Bennett's principles and practice of infectious diseases 7th ed. Churchill Livingstone\/Elsevier Philadelphia PA."},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00721-09"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dkq116","article-title":"Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation","volume":"65","author":"Nix DE","year":"2010","unstructured":"NixDE MatthiasKR. 2010. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J. Antimicrob. Chemother. 65:1311\u20131312.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq346"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010193"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00387-11"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"Senol S","year":"2010","unstructured":"SenolS. 2010. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J. Chemother. 22:355\u2013357.","journal-title":"J. Chemother."},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/0036554021000026985","article-title":"Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin","volume":"35","author":"Shrestha NK","year":"2003","unstructured":"ShresthaNK. 2003. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand. J. Infect. Dis. 35:12\u201314.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01086-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00402-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00402-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:01:04Z","timestamp":1645480864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00402-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.00402-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00402-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}